Director Ajay Nirula files initial Form 3 for Zura Bio Ltd (ZURA)

Rhea-AI Filing Summary

Zura Bio Ltd director Ajay Nirula filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and does not report any insider purchase, sale, acquisition, or disposition transactions in the summarized data.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nirula Ajay

(Last) (First) (Middle)

C/O ZURA BIO LTD

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/21/2026

3. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Kim Davis, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Zura Bio Ltd (ZURA) Form 3 filing report?

The Form 3 filing reports that Ajay Nirula is a director of Zura Bio Ltd. It serves as his initial statement of beneficial ownership, with no insider transactions listed in the summarized data.

Who is the reporting person in the Zura Bio Ltd (ZURA) Form 3?

The reporting person is Ajay Nirula, identified in the filing as a director of Zura Bio Ltd. The metadata confirms his director status and shows no officer role or other listed positions.

Does the Zura Bio Ltd (ZURA) Form 3 show any insider trades by Ajay Nirula?

No, the summarized data shows no reported insider trades. Buy, sell, acquire, and dispose transaction counts are all zero, indicating no reportable transactions in this Form 3 excerpt.

Is Ajay Nirula a 10% owner of Zura Bio Ltd (ZURA) according to this Form 3?

According to the provided data, Ajay Nirula is not flagged as a 10% owner. The ten-percent-owner indicator is set to zero, while he is identified specifically as a director of the company.

What is the purpose of Ajay Nirula’s Form 3 for Zura Bio Ltd (ZURA)?

The purpose is to provide an initial statement of beneficial ownership as he serves as a director of Zura Bio Ltd. It establishes his reporting status, with no insider transactions shown in the summarized information.